Life Science Compliance Update

December

2017

The Ongoing Struggles of Novartis’ Global Compliance Function

Written by , Posted in Uncategorized

Robert N. Wilkey, Esq., Staff Writer and Seth Whitelaw, J.D., LL.M., S.J.D., Editor for Life Science Compliance Update

In recent months, the pharmaceutical company Novartis, has been hit with some high profile international corruption scandals in South Korea and Greece. Although such large-scale scandals involving pharmaceutical and medical device companies is nothing new, the Novartis case study brings to light the challenges of providing effective compliance for life science companies actively engaged in market expansion abroad. In this article, we will briefly examine how Novartis is working to address those challenges. However, in the end, meeting that challenge is going to take cultural savvy, flexibility and above all stamina.


   or   


November

2017

Why it matters – Pharmaceutical compliance, Anti-corruption and Access to Medicine

Written by , Posted in Uncategorized

Luca Genovese and Danny Edwards, The Access to Medicine Foundation

Access to medicine continues to be out of reach for an estimated two billion people worldwide. While it is clear that corruption plays a role in that problem, the true scope and cost of global health corruption is unknown. This article examines what pharmaceutical companies do and what role they should play in eliminating corruption as part of the equation of ensuring access.


   or   


Gravityscan Badge
Menu Title